Publications
1. Hoffman E, Brogden M, Palmer J. The use of sucrose as a cryoprotective agent for sheep erythrocyte-complement component intermediate EAC142. J Immunol Met 10:293-299, 1976.
2. Smith J, Everett ED. Unilateral hypertrophic osteoarthropathy: a clue to aortoenteric fistulas. Missouri Med 80:304-305, 1983.
3. Smith J, Muscato M, Walls J et al. Extracorporeal circulation in a patient with heparin induced thrombocytopenia. Anesthesiology 62:363-365, 1985.
4. Smith J. Drug overdoses: Changing concepts for drugs of the eighties. S Med J 79:1230-1233, 1986.
5. Smith J, Solomon TE. Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer. Gastroenterology 95:1541-1548, 1988.
6. Smith JP, Wood JG, Solomon TE. Elevated gastrin levels in patients with colon cancer or adenomatous polyps. Dig Dis Sci 34:171-174, 1989.
7. Smith JP, Burns TW, Leigh CC. Diabetes mellitus and lipoatrophy. S Med J 83:573-576, 1990.
8. Smith JP, Kramer S, Bagheri S. Effects of a high fat diet and L364,718 on growth of human pancreas cancer. Dig Dis Sci 35:726-732, 1990.
9. Smith JP, Solomon TE, Bagheri S, Kramer S. Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990. Dig Dis Sci 35:1377-1384, 1990.
10. Smith J, Kramer ST, Solomon TE. CCK stimulates growth of six human pancreatic cancer cell lines in serum-free medium. Reg Peptides 32:341-349, 1991.
11. Smith JP, Kramer S, Bagheri S. Effects of pancreastatin (24-49) on growth of normal pancreas and pancreatic cancer. Pancreas 6:551-557, 1991.
12. McGarrity TJ, Peiffer LP, Kramer ST, Smith JP. The effects of a high fat and fiber diet on human colon cancer xenografted to athymic nude mice. Dig Dis Sci 36:1606-1610, 1991.
13. Smith JP, Kramer ST, Cheung JY. Effects of cholecystokinin on cytosolic calcium in human pancreatic cancer cells. Reg Peptides 36:299-310, 1991.
14. Heald EB, Kramer ST, Smith JP. Trophic effect of unsulfated cholecystokinin on mouse pancreas and human pancreatic cancer. Pancreas 7:530-535, 1992.
15. Smith JP, Kramer ST, Demers LM. Effects of gastrin and DFMO on growth of human colon cancer. Dig Dis Sci 38:520-528, 1993.
16. Smith JP, Yelamarty RV, Kramer ST, Cheung JY. Effects of cholecystokinin on cytosolic calcium in pancreatic duct segments and ductal cells. Am J Physiol 264:G1177-G1183, 1993.
17. Smith JP, Rickabaugh CA, McLaughlin PJ, Zagon IS. Cholecystokinin receptors and PANC-1 human pancreatic cancer cells. Am J Physiol 265:G149-G155, 1993.
18. Smith JP, Liu G, Soundararajan V, McLaughlin PJ, Zagon IS. Identification and characterization of CCK-B/gastrin receptors in human pancreatic cancer cell lines. Am J Physiol 266:R277-R283, 1994.
19. Smith JP, Doll D, Croitoru R, Thornton C, Perry MC. Effects of octreotide on advanced colon cancer. J Clin Gastroenterol 18:245-247, 1994.
20. Swift I, Smith JP. CCK analog, JMV-180, stimulates growth of human pancreatic cancer. Dig Dis Sci 39:1007-1013,1994.
21. Smith JP. Zagon IS. Cholecystokinin receptors and human pancreatic adenocarcinoma. Int J Pancreatology 16:243-246,1994.
22. Smith JP, Liu G Stock E, Orenberg EK, Yu NY, Brown DM. Intratumoral chemotherapy with intradose drug delivery system inhibits growth of human pancreatic cancer xenografts. Int J Pancreatology 16:298-300, 1994.
23. Smith JP, Fantaskey AP, Liu G, Zagon IS. Identification of gastrin as a growth peptide in human pancreatic cancer. Am J Physiol 268:R135-R141, 1995.
24. Smith JP, Stock EA, Orenberg EK, Yu NY, Kanekal S, Brown DM. Intratumoral chemotherapy with sustained-release drug delivery system inhibits growth of human pancreatic cancer xenografts. Anti-Cancer Drugs 6:717-726, 1995.
25. Smith JP, Shih A, Wu Y, McLaughlin PJ, Zagon IS. Gastrin regulates growth of human pancreatic cancer in a tonic and autocrine fashion. Am J Physiol 270(5 Pt 2):R1078-R1084, 1996.
26. Hytrek S, Smith JP, McGarrity TJ, McLaughlin PJ, Lang MC, Zagon IS. Identification and characterization of zeta opioid receptor in human colon cancer. Am J Physiol 271:R115-R121, 1996.
27. Smith JP, Stock E, Wotring MG, McLaughlin PJ, Zagon IS. Characterization of the CCK-B/gastrin-like receptor in human colon cancer. Am J Physiol 271:R796-R805, 1996.
28. Zagon IS, Hytrek SD, Lang CM, Smith JP, McGarrity TJ, McLaughlin PJ, Wu Y. Opioid growth factor
([Met5]-enkephalin) prevents the incidence and retards the growth of human colon cancer. Am J Physiol 271(3 Pt 2):R780-R786, 1996.
29. Zagon IS, Hytrek SD, Smith JP, McLaughlin PJ. Opioid growth factor (OGF) inhibits human pancreatic cancer transplanted into nude mice. Cancer Letters 112:167-175, 1997.
30. Smith JP. Treatment of chronic hepatitis C with Amantadine-hydrochloride. Dig Dis and Sci 42:1681-1687, 1997.
31. Riley TR, Smith JP. Ibuprofen induced hepatotoxicity in those with chronic hepatitis C: A case series. Amer J Gastro, 93:1563-1565, 1998.
32. Smith JP, Shih AH, Wotring MG, McLaughlin PJ, Zagon IS. Characterization of CCK-B/gastrin-like receptors in human gastric carcinoma. Int J Oncol 12:411-419, 1998.
33. Smith JP, Hamory MW, Verderame MF, Zagon IS. Quantitative analysis of gastrin in RNA and peptide in normal and cancerous human pancreas. Int J Mol Med 2:309-315, 1998.
34. Leitzel K, Lieu B, Curley E, Smith J, Chinchilli V, Rychlik W, Lipton A. Detection of Cancer cells in peripheral blood of breast cancer patients using RT-PCR for epidermal growth factor receptor. Clin Cancer Res 4:3037-3043, 1998.
35. Smith JP, Kanekal S, Patawaran MB, Chen JY, Jones RE, Orenberg EK, Yu NY. Drug retention and distribution after intratumoral chemotherapy with fluorouracil/epinephrine injectable gel in human pancreatic cancer xenografts. Cancer Chemo Pharm 44:267-274, 1999.
36. Smith JP, Verderame MF, Zagon IS. Antisense oligonucleotides to gastrin inhibit growth of human pancreatic cancer. Cancer Lett 135:107-112, 1999.
37. Zagon IS, Smith JP, McLaughlin, PJ. Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor. Int J Oncol 14:577-584, 1999.
38. Riley TR, Smith JP. Preventive care in chronic liver disease. J Gen Intern Med 14:699-704, 1999.
39. Zagon IS, Smith JP, Conter R, McLaughlin PJ. Identification and characterization of opioid growth factor receptor (OGFr) in human pancreatic adenocarcinoma. Int J Mol Med 5:77-84, 2000.
40. Smith JP, Conter RL, Demers LM, McLaughlin PJ, Zagon IS. Elevated levels of opioid growth factor in the plasma of patients with pancreatic cancer. Pancreas 21:158-164, 2000.
41. Smith JP, Verderame MF, McLaughlin PJ, Martenis M, Ballard E, Zagon IS. Characterization of the CCK-C (cancer) receptor in human pancreatic cancer. Int J Mol Med 10:689-694, 2002.
42. Clarke, L, Leitzel K, Smith J, Ali S, Lipton A. Detection of EGFR-positive circulating cancer cells in the blood of solid tumor patients. Intr J Oncol 22:425-430, 2002.
43. Smith JP, Conter RL, Bingaman SI, Harvey HA, Mauger DT, Ahmad M, Demers LM, Stanley WB, McLaughlin PJ, Zagon IS. Treatment of advanced pancreatic cancer with opioid growth factor: phase I. Anti-Cancer Drugs 15:203-209, 2004.
44. Smith JP, Verderame MF, Ballard EN, Zagon IS. Functional significance of gastrin gene expression in human cancer cells. Regul Peptides 117:167-173, 2004.
45. Smith JP, Riley TR, Devenyi A, Bingaman SI, Kunselman A. Amantadine therapy for chronic hepatitis C: A randomized double-blind placebo-controlled trial. J Gen Intern Med 19:662-668, 2004.
46. Smith JP, Riley TR, Bingaman S, Mauger DT. Amantadine therapy for chronic hepatitis C: A dose escalation study. Am J Gastro 99:1099-1104, 2004.
47. Smith JP, Stanley WB, Verderame MF, Zagon IS. The functional significance of the cholecystokinin-C (CCK-C) receptor in human pancreatic cancer. Pancreas 29:271-277, 2004.
48. Zagon IS, Jaglowski JR, Verderame MF, Smith JP, Leure-duPree AE, McLaughlin PJ. Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma. Cancer Chemother Pharmacol 56:510-520, 2005.
49. Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon, IS. Low-dose naltrexone therapy improves active Crohn’s disease. Am J Gastroenterology: 102:1-9, 2007.
50. Smith JP, Zagon I, Matters G, Harms J, McGovern C, Fitzpatrick L, Stock H, Bingaman S, Mauger D, Parikh A, Nilo N. The opioid antagonist, naltrexone improves inflammatory bowel disease. Immune-Med Dis: 11(suppl 2):54, 2007.
51. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, Bloomfield R, and Sandborn WJ, for the PRECISE 2 Study Investigators (includes Smith JP). Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 2007;357:239-50.
52. Matters GL, Harms JF, McGovern C, Fitzpatrick L, Parikh A, Nilo N, and Smith JP. The opioid antagonist naltrexone improves murine inflammatory bowel disease. J Immunotoxicology: Apr;5(2):179-87, 2008.
53. Stock H, Kadry Z, Smith JP. Surgical management of portal hypertension in Felty’s syndrome: A case report and literature review. J Hepatology 50:831-35, 2009.
54. Matters GL, Harms JF, McGovern CO, Jayakumar C, Crepin K, Smith ZP, Nelson MC, Stock H, Fenn CW, Kaiser J, Kester, and Smith JP. Growth of pancreatic cancer is inhibited by down-regulation of gastrin gene expression. Pancreas 38: e151-161, 2009
55. Smith JP, Bingaman SI, Mauger DT, Harvey HH, Demers LM, and Zagon IS. Opioid growth factor (OGF) improves clinical benefit and survival in patients with advanced pancreatic cancer. Open Access Journal of Clinical Trials 2010:2, 1-12.
56. Barth BM, Sharma R, Altınoğlu Eİ, Morgan TT, Shanmugavelandy SS, Kaiser JM, McGovern C, Matters GL, Smith JP, Kester M, Adair JH. Bioconjugation of calcium phosphosilicate composite nanoparticles for selective targeting of human breast and pancreatic cancers in vivo. In ACS Nano. American Chemical Society, 2010, http://dx.doi.org/10.1021/nn901297q.
57. McHutchison JG, Manns MP, Muir AJ, et al, (for the PROVE3 team – includes Smith JP). Telaprevir for previously treated chronic HCV infection. N Engl J Med 362(14):1292-1303, 2010.
58. Matters GL, McGovern C, Harms JF, Markovic K, Anson K, Jayakumar C, Martenis M, Awad C, Smith JP. Role of endogenous cholecystokinin on growth of pancreatic cancer. Int J Oncol, 2011, 38:593-601.
59. Smith JP, Bingaman SI, Ruggiero F, Mauger DT, Mukherjee A, McGovern CO, Zagon IS. Therapy with the Opioid Antagonist Naltrexone Promotes Mucosal Healing in Active Crohn’s Disease: a Randomized Placebo-Controlled Trial. Dig Dis & Sci. 2011.
60. Smith JP, Harms, JF, Matters, GL, McGovern CO, Fino KK, Ortega EE, Ruggiero FM, Liao J, Phillips III JA. Survival of Pancreatic Cancer is Associated with a Single Nucleotide Polymorphism of the Cholecystokinin-B Receptor. Gastroenterology 2011 (under revision).
